| Precision medicine and nucleotide-based therapeutics to treat MASH |
Andrea Caddeo1, Stefano Romeo2,3,4,5
|
1Department of Biomedical Sciences, Unit of Oncology and Molecular Pathology, University of Cagliari, Cagliari, Italy
2Clinical Nutrition Unit, Department of Medical and Surgical Sciences, University Magna Graecia, Catanzaro, Italy
3Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden
4Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden
5Department of Medicine, Endocrinology (H7) Karolinska Institute and hospital, Huddinge, Stockholm, Sweden |
|
|
|
Received: June 8, 2024 Revised: July 31, 2024 Accepted: August 4, 2024 |
|
|
|
| ABSTRACT |
|
|
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a complex multifactorial disease and becoming the leading cause of liver-related morbidity and mortality. MASLD spans from isolated steatosis to metabolic dysfunction-associated steatohepatitis (MASH), that may progress to cirrhosis and hepatocellular carcinoma (HCC). Genetic, metabolic, and environmental factors strongly contribute to the heterogeneity of MASLD. Lifestyle intervention and weight loss represent a viable treatment for MASLD. Moreover, Resmetirom, a thyroid hormone beta receptor agonist, has recently been approved for MASLD treatment. However, most individuals treated did not respond to this therapeutic suggesting the need for a more tailored approach to treat MASLD.
Oligonucleotide-based therapies, namely small-interfering RNA (siRNA) and antisense oligonucleotide (ASO), have been recently developed to tackle MASLD by reducing the expression of genes influencing MASH progression, such as PNPLA3 and HSD17B13. Here, we review the latest progress made in the synthesis and development of oligonucleotide-based agents targeting genetic determinants of MASH. |
| KeyWords:
MASLD, MAFLD, human genetics, drug |
|
|
PDF Links
Full text via DOI
Download Citation
